Literature DB >> 19710582

Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada.

Philippe De Wals1, Michel Carbon, Elodie Sévin, Geneviève Deceuninck, Manale Ouakki.   

Abstract

BACKGROUND: In Canada, a 7-valent pneumococcal conjugate vaccine (PCV-7) was licensed in 2001, and free vaccination of children <5 years of age was offered in December 2004 in the province of Quebec.
OBJECTIVES: To describe the frequency of physician claims for otitis media (OM) in relation to PCV-7 coverage during the period from 1996 to 2007.
METHODS: The monthly frequency of OM claims in the population aged <10 years was obtained from the provincial health insurance board. Time series in different age categories were analyzed using structural models with unobserved components, including seasonality, linear trends, level changes, and outliers. The candidate explanatory variable was PCV-7 uptake rate as measured in the population <5 years of age in the Quebec City area.
RESULTS: Free PCV-7 program implementation was followed by a marked increase in uptake and by the end of 2007, >90% of children had received >or=1 dose. In all models, seasonality was a major determinant of OM frequency rates and there were statistically significant downward trends, as well as downward level breaks and outliers. PCV-7 coverage (>or=1 dose) was a significant predictor in children 6 months to 2 years of age. The effect was of lesser magnitude and not significant in the group of children aged 2 to 4 years, and absent in the group 5 to 9 years. Since PCV-7 licensure, an estimated 100,000 visits were averted in children <5 years of age, and OM claim frequency reduction attributable to PCV-7 was 13.2% by the end of the study period.
CONCLUSION: PCV-7 implementation was associated with a significant reduction in the frequency of OM in the target population, and there was no indication of herd protection in older children.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19710582     DOI: 10.1097/INF.0b013e3181bad212

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  25 in total

1.  Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of acute otitis media, recurrent otitis media and tympanostomy tube insertion in children after its implementation into the national immunization program in Turkey.

Authors:  Ahmet Soysal; Erdem Gönüllü; Ismail Yıldız; Gökhan Aydemir; Turan Tunç; Yezdan Fırat; Burak Erdamar; Metin Karaböcüoğlu
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

Review 2.  The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Authors:  Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

3.  Decline in early childhood respiratory tract infections in the Norwegian mother and child cohort study after introduction of pneumococcal conjugate vaccination.

Authors:  Maria C Magnus; Didrik F Vestrheim; Wenche Nystad; Siri Eldevik Håberg; Hein Stigum; Stephanie J London; Marianne A R Bergsaker; Dominique A Caugant; Ingeborg S Aaberge; Per Nafstad
Journal:  Pediatr Infect Dis J       Date:  2012-09       Impact factor: 2.129

4.  Pneumococcal conjugate vaccines for preventing otitis media.

Authors:  Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2016-03       Impact factor: 2.253

5.  Pneumococcal Phenotype and Interaction with Nontypeable Haemophilus influenzae as Determinants of Otitis Media Progression.

Authors:  Joseph A Lewnard; Noga Givon-Lavi; Paula A Tähtinen; Ron Dagan
Journal:  Infect Immun       Date:  2018-05-22       Impact factor: 3.441

Review 6.  A second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children.

Authors:  Carlos G Grijalva; Stephen I Pelton
Journal:  Curr Opin Pediatr       Date:  2011-02       Impact factor: 2.856

7.  Respiratory infection and otitis media visits in relation to pneumococcal conjugate vaccine use in Saskatchewan.

Authors:  Ngoc-Hang Khuc; Ben Tan; Rosalie Tuchscherer; Nigel Sb Rawson; Philippe De Wals
Journal:  Can J Infect Dis Med Microbiol       Date:  2013       Impact factor: 2.471

8.  Update on acute otitis media in children younger than 2 years of age.

Authors:  Colin J McWilliams; Ran D Goldman
Journal:  Can Fam Physician       Date:  2011-11       Impact factor: 3.275

Review 9.  Panel 6: Vaccines.

Authors:  Stephen I Pelton; Melinda M Pettigrew; Stephen J Barenkamp; Fabrice Godfroid; Carlos G Grijalva; Amanda Leach; Janak Patel; Timothy F Murphy; Sanja Selak; Lauren O Bakaletz
Journal:  Otolaryngol Head Neck Surg       Date:  2013-04       Impact factor: 3.497

10.  Impact of pneumococcal conjugate vaccines on microbial epidemiology and clinical outcomes of acute otitis media.

Authors:  Isabelle Hau; Corinne Levy; Laurence Caeymaex; Robert Cohen
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.